4.8 Article

In vitro and in vivo characterisation of a novel peptide delivery system: Amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes

期刊

JOURNAL OF CONTROLLED RELEASE
卷 147, 期 2, 页码 289-297

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2010.07.128

关键词

Salmon calcitonin; Poly(allyl)amine; Amphiphilic polymers; Oral peptide delivery; Peptidase inhibition

资金

  1. Science Foundation Ireland [07 SRC/B1154]
  2. Cunningham Trust [ACC/KWF/CT07/09]

向作者/读者索取更多资源

The cationic peptide, salmon calcitonin (sCT) was complexed with the cationic amphiphilic polyelectrolyte, poly(allyl)amine, grafted with palmitoyl and quaternary ammonium moieties at pH 5.0 and 7.4 to yield particulates (sCT-QPa). The complexes were approximately 200 nm in diameter, had zeta potentials ranging from +20 to +50 mV, and had narrow polydispersity indices (PDIs). Differential scanning calorimetry revealed the presence of an interaction between sCT and QPa in the complexes. Electron microscopy confirmed the zeta-size data and revealed a vesicular bilayer structure with an aqueous core. Tyrosine- and Nile red fluorescence indicated that the complexes retained gross physical stability for up to 7 days, but that the pH 5.0 complexes were more stable. The complexes were more resistant to peptidases, serum and liver homogenates compared to free sCT. In vitro bioactivity was measured by CAMP production in T47D cells and the complexes had EC50 values in the nM range. While free sCT was unable to generate CAMP following storage for 7 days, the complexes retained approximately 33% activity. When the complexes were injected intravenously to rats, free and complexed sCT (pH 5.0 and 7.4) but not QPa reduced serum calcium over 120 min. Free and complexed sCT but not QPa also reduced serum calcium over 240 min following intrajejunal administration. In conclusion, sCT QPa nanocomplexes that have been synthesised are stable, bioactive and resistant to a range of peptidases. These enhanced features suggest that they may have the potential for improved efficacy when formulated for injected and oral delivery. (C) 2010 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据